Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 6/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30096055 | 0.87 | CA1 (0.44) | CA1CA2CA7CTSKCA4 | |
| SCHEMBL30783133 | 0.86 | CA1 (0.40) | CA1CA2CA7CTSKCA4 | |
| SCHEMBL30783132 | 0.76 | CA1 (0.46) | CA1CA2CA7CTSKCA4 | |
| SCHEMBL27220600 | 0.75 | ALDH1A1 (0.37) | SMN1; SMN2 | |
| SCHEMBL30096052 | 0.73 | GLO1 (0.38) | SMN1; SMN2 | |
| SCHEMBL24170368 | 0.66 | CYP2D6 (0.49) | SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL20877749 | 0.64 | CA1 (0.59) | CA1CA2CA7CTSKCA4 | |
| SCHEMBL31402184 | 0.64 | CA1 (0.59) | CA1CA2CA7CTSKCA4 | |
| SCHEMBL26239946 | 0.63 | CA1 (0.67) | CA1CA2CA7CTSKCA4 | |
| SCHEMBL20942487 | 0.63 | CYP2D6 (0.41) | CTSKSMN1; SMN2CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317692-A1 | METHOD FOR PRODUCING URACIL COMPOUND | NIPPON SODA CO., LTD. (JP) | 2024-09-26 | — | — | US | disclosed |
| EP-4371978-A1 | METHOD FOR PRODUCING URACIL COMPOUND | Nippon Soda Co., Ltd. (JP) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023286719-A1 | METHOD FOR PRODUCING URACIL COMPOUND | 日本曹達株式会社 | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317692-A1 | METHOD FOR PRODUCING URACIL COMPOUND | UMPS, NUDT1, DPYD | CA1 1451/4885CA2 1951/4885CA7 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.